Jan-Philipp Mallm

Jan-Philipp Mallm

Auto-generated profile, based on publicly available information

Jan-Philipp Mallm

Single-cell Open Lab, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Nature
Verified
Journal Article
Open access
PDF file
DPDominik Pfister
Dominik Pfister
NNNicolás Gonzalo Núñez
Nicolás Gonzalo Núñez
RPRoser Pinyol
Roser Pinyol
OGOlivier Govaere
Olivier Govaere
MPMatthias Pinter
Matthias Pinter
MHMathias Heikenwälder
Mathias Heikenwälder
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

24 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MDMichael Dudek
Michael Dudek
DPDominik Pfister
Dominik Pfister
SDSainitin Donakonda
Sainitin Donakonda
PFPamela Filpe
Pamela Filpe
ASAnnika Schneider
Annika Schneider
PKPercy A. Knolle
Percy A. Knolle

15 June 2020 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
TRTobias Roider
Tobias Roider
JSJulian Seufert
Julian Seufert
AUAlexey Uvarovskii
Alexey Uvarovskii
FFFelix Frauhammer
Felix Frauhammer
MBMarie Bordas
Marie Bordas
SDSascha Dietrich
Sascha Dietrich
Tumour heterogeneity encompasses both the malignant cells and their microenvironment. While heterogeneity between individual patients is known to affect the efficacy of cancer therapy, most personalized treatment approaches do not account for intratumour heterogeneity. We addressed this issue by studying the heterogeneity of nodal B-cell lymphomas by single-cell RNA-sequencing and transcriptome-informed flow cytometry. We identified transcriptionally distinct malignant subpopulations and compared their drug-response and genomic profiles. Malignant subpopulations from the same patient responded strikingly differently to anti-cancer drugs ex vivo, which recapitulated subpopulation-specific drug sensitivity during in vivo treatment. Infiltrating T cells represented the majority of non-malignant cells, whose gene-expression signatures were similar across all donors, whereas the frequencies of T-cell subsets varied significantly between the donors. Our data provide insights into the heterogeneity of nodal B-cell lymphomas and highlight the relevance of intratumour heterogeneity for personalized cancer therapy.

4 November 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MSMehmet Saçma
Mehmet Saçma
JPJohannes Pospiech
Johannes Pospiech
RBRuzhica Bogeska
Ruzhica Bogeska
WBWalter de Back
Walter de Back
JMJan-Philipp Mallm
Jan-Philipp Mallm
Maria Carolina FlorianMaria Carolina Florian
Maria Carolina Florian

1 June 2015 in Cell Reports
Verified
Journal Article
Open access
JMJan-Philipp Mallm
Jan-Philipp Mallm
KRKarsten Rippe
Karsten Rippe
Non-coding RNAs can modulate histone modifications that, at the same time, affect transcript expression levels. Here, we dissect such a network in mouse embryonic stem cells (ESCs). It regulates the activity of the reverse transcriptase telomerase, which synthesizes telomeric repeats at the chromosome ends. We find that histone H3 serine 10 phosphorylation set by Aurora kinase B (AURKB) in ESCs during the S phase of the cell cycle at centromeric and (sub)telomeric loci promotes the expression of non-coding minor satellite RNA (cenRNA). Inhibition of AURKB induces silencing of cenRNA transcription and establishment of a repressive chromatin state with histone H3 lysine 9 trimethylation and heterochromatin protein 1 accumulation. This process results in a continuous shortening of telomeres. We further show that AURKB interacts with both telomerase and cenRNA and activates telomerase in trans. Thus, in mouse ESCs, telomere maintenance is regulated via expression of cenRNA in a cell-cycle-dependent manner.

28 August 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JMJan‐Philipp Mallm
Jan‐Philipp Mallm
PWPaul Windisch
Paul Windisch
ABAlva Biran
Alva Biran
ZGZoltan Gal
Zoltan Gal
SSSabrina Schumacher
Sabrina Schumacher
KRKarsten Rippe
Karsten Rippe
Tumor‐initiating cells are a subpopulation of cells that have self‐renewal capacity to regenerate a tumor. Here, we identify stem cell‐like chromatin features in human glioblastoma initiating cells (GICs) and link them to a loss of the repressive histone H3 lysine 9 trimethylation (H3K9me3) mark. Increasing H3K9me3 levels by histone demethylase inhibition led to cell death in GICs but not in their differentiated counterparts. The induction of apoptosis was accompanied by a loss of the activating H3 lysine 9 acetylation (H3K9ac) modification and accumulation of DNA damage and downregulation of DNA damage response genes. Upon knockdown of histone demethylases, KDM4C and KDM7A both differentiation and DNA damage were induced. Thus, the H3K9me3–H3K9ac equilibrium is crucial for GIC viability and represents a chromatin feature that can be exploited to specifically target this tumor subpopulation.